3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
4
Melanoma
4
Small Cell Lung Carcinoma
3
Prostatic Neoplasms, Castration-Resistant
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC Harboring NRG1 Fusion
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
Carboplatin
71
Paclitaxel
49
Radiotherapy
44
Pemetrexed
42
Cisplatin
41
Bevacizumab
39
Gemcitabine
27
Docetaxel
27
Erlotinib Hydrochloride
23
Gefitinib
18
pembrolizumab
14
Taxes
13
Vinorelbine
10
Cetuximab
10
Radiation
8
Nivolumab
8
Magnetic Resonance Spectroscopy
8
capmatinib
7
Radiosurgery
7
Platinum
7
Etoposide
7
Surgical Procedures, Operative
6
Radiotherapy, Conformal
6
Mastectomy, Segmental
6
ceritinib
5
aflutinib
5
Specimen Handling
5
Neoadjuvant Therapy
5
Cyclophosphamide
5
Biopsy
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
enzalutamide
×
Thoracic
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled